Mobile

A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjug...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000560-93

A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or PrevenarTM in study 10PN-PD-DIT-003 (105554), via the administration of a single booster dose of a 23-valent pneumococcal plain polysaccharide vaccine

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunological memory following primary vaccination with either GSK Biologicals’ 10-valent conjugate vaccine or Prevenar™, through the administration of a single booster dose of unconjugated 23-valent pneumococcal polysaccharide vaccine (Pneumovax™23) in children 11-14 months of age.

Critère d'inclusion

  • A single dose of Sanofi Pasteur MSD’s unconjugated 23-valent polysaccharide pneumococcal vaccine (Pneumovax™23) to healthy children who were previously primed with the full three doses of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ in the primary vaccination study 10PN-PD-DIT-003. Children will be 11-14 months old at the time of enrolment in this study and will receive concomitantly their booster dose of Infanrix™hexa according to national recommendations

Liens